Sign In
Buy PFE
$25.36
-0.200 (-0.783%)
At Close: Jun 03, 2026
Arrow Capital Pty Ltd Acquires New Shares in Pfizer Inc. $PFE
03:26am, Wednesday, 10'th Dec 2025
Arrow Capital Pty Ltd purchased a new position in Pfizer Inc. (NYSE: PFE) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The
Down 50%, Should You Buy the Dip on Pfizer?
04:15pm, Tuesday, 09'th Dec 2025
Pfizer is one of the world's largest drugmakers. It has long managed to produce new blockbuster drugs to replace drugs losing patent protection.
Will Pfizer's YaoPharma deal deliver a powerful new oral obesity pill?
03:30pm, Tuesday, 09'th Dec 2025
Pfizer is rolling the dice again on an oral obesity pill. The pharmaceutical giant signed an exclusive global license agreement with YaoPharma, a subsidiary of China's Fosun Pharma.
Pfizer Expands Obesity Pipeline With Up to $2.1 Billion Deal for YaoPharma Pill
12:30pm, Tuesday, 09'th Dec 2025
Pfizer (PFE, Financials) on Tuesday signed an agreement worth up to $2.1 billion with China-based YaoPharma to develop and commercialize the company's oral obes
Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill
11:14am, Tuesday, 09'th Dec 2025
Pfizer said it has struck an up to $2.1 billion licensing deal with YaoPharma to develop and commercialize its obesity pill, furthering the pharma company's push into the weight loss space. YaoPharm
Undisclosed Deaths in the Pfizer mRNA COVID-19 Vaccine Trial Discussed in the Journal of American Physicians and Surgeons
10:59am, Tuesday, 09'th Dec 2025
In the rushed emergency use approval of Covid vaccines, deaths were undisclosed. Thousands received shots before warnings of heart damage were released.
Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains
10:45am, Tuesday, 09'th Dec 2025
Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, despite near-term headwinds. PFE maintains strong free cash flow and improved gui
Here's 12 Ideal 'Safer' December Dividend Dogs Of The S&P500
10:15am, Tuesday, 09'th Dec 2025
S&P 500 high-yield 'safer' dividend stocks offer attractive upside, with twelve currently meeting the dogcatcher ideal of dividends exceeding share prices. Analyst targets forecast 21.14% to 44.05% ne
Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement
06:55am, Tuesday, 09'th Dec 2025
SHANGHAI , Dec. 9, 2025 /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pha
Pfizer partners with YaoPharma for weight management treatment
06:38am, Tuesday, 09'th Dec 2025
Pfizer said on Tuesday it had entered into an exclusive licensing agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical, for the development and commercialization of an experimental
Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
06:30am, Tuesday, 09'th Dec 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceut
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophi
Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue
08:52am, Saturday, 06'th Dec 2025
Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions.
Do These 3 Healthcare Stocks Need a Checkup?
04:05pm, Friday, 05'th Dec 2025
Pfizer has a sizable 6.8% yield and is down nearly 60% from its 2021 highs. Bristol Myers Squibb has a 5% yield and is off its 2023 highs by nearly 40%.
2 Headwinds Facing Pfizer Stock Going Into 2026
10:05am, Friday, 05'th Dec 2025
Pfizer's coronavirus vaccine could face some headwinds in the near future. The company will enter a period of patent cliffs next year.
